ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

DYNAMICS OF C-REACTIVE PROTEIN LEVELS IN CHILDREN WITH CYSTIC FIBROSIS IN THE ARAL SEA REGION

Yakubov D.M., Bekchanov B.G., Qabulov B.M.
Urganch State Medical Institute
https://orcid.org/ORCID:0009-0006-9399-2257

Annotation: In recent years, cystic fibrosis, an autosomal recessive hereditary disease caused by a pathogenic variant of the nucleotide sequence (mutation) of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, has been diagnosed more and more in children worldwide. To date, the increasing incidence, insufficient understanding of the pathogenetic mechanisms, specific features of the clinical course, and the emergence of severe complications of cystic fibrosis require scientific research on this nosology.

Key words: Management and treatment of bronchopulmonary pathology in children with cystic fibrosis.

ОРОЛБЎЙИ МИНТАҚАСИДАГИ МУКОВИСЦИДОЗЛИ БОЛАЛАРДА С-РЕАКТИВ ОҚСИЛ КЎРСАТКИЧЛАРИ ДИНАМИКАСИ

Якубов Д.М., Бекчанов Б.Г., Кабулов Б.М.
Урганч давлат тиббиёт институти
https://orcid.org/ORCID:0009-0006-9399-2257

Аннотация: Дунёда сўнгги йилларда муковисцидоз трансмембран ўтказувчанлиги регулятори (Cystic Fibrosis Transmembrane Conductance Regulator, CFTR) гени нуклеотид кетма-кетлиги (мутация)ининг патоген варианти туфайли келиб чиқувчи, наслдан наслга ўтувчи аутосом-рецессив тури бўлган ирсий касаллик – муковисцидоз (*c*ystic fibrosis) болаларда кундан-кунга кўпроқ ташхисланмоқда. Бугунги кунга келиб касалланиш даражасининг ортиши, патогенетик механизмлари, клиник кечишининг ўзига хос хусусиятлари етарлича ўрганилмаганлиги, муковисцидознинг оғир асоратлари юзага келаётганлиги ушбу нозология бўйича илмий тадқиқотлар олиб борилиши зарурлигини тақозо этмоқда.

Калит сузлар: Муковисцидоз билан касалланган болаларда бронх-ўпка патологиясини олиб бориш ва даволаш.

ДИНАМИКА ПОКАЗАТЕЛЕЙ С-РЕАКТИВНОГО БЕЛКА У ДЕТЕЙ С МУКОВИСЦИДОЗОМ В РЕГИОНЕ ПРИАРАЛЬЯ

Якубов Д.М., Бекчанов Б.Г., Кабулов Б.М.
Ургенчского государственного медицинского института
https://orcid.org/ORCID:0009-0006-9399-2257

Аннотация: В последние годы муковисцидоз – аутосомно-рецессивное наследственное заболевание, обусловленное патогенным вариантом нуклеотидной последовательности (мутацией) гена трансмембранного регулятора проводимости муковисцидоза (CFTR), – всё чаще диагностируется у детей во всём мире. Рост заболеваемости, недостаточное понимание

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

патогенетических механизмов, особенностей клинического течения и возникновение тяжёлых осложнений муковисцидоза требуют проведения научных исследований в этой нозологии.

Ключевые слова: Ведение и лечение бронхолегочной патологии у детей с муковисцидозом.

Relevance: A number of scientific studies are being conducted worldwide to study the early diagnosis, treatment, and clinical and pathogenetic aspects of cystic fibrosis in children. In this regard, identifying risk factors for the development of cystic fibrosis in children, assessing the role of vitamin D, determining the state of inflammatory markers and mediators of the immune response based on modern clinical data and diagnostic methods, and developing personalized approaches to treating the disease are among the urgent problems of today.

In our country, extensive work is currently being carried out to improve the healthcare system and social protection of the population, adapt the medical system to the requirements of world standards, and promote early diagnosis, treatment and prevention of hereditary orphan diseases. In order to raise the level of medical services to a new level, important tasks have been set: "...strengthening family health, protecting motherhood and childhood, expanding access to quality medical services for mothers and children, providing them with specialized and high-tech medical care, and further implementing comprehensive measures to reduce infant and child mortality." In implementing these tasks, new aspects of the prevalence of cystic fibrosis, identifying risk factors affecting the development of the disease, strengthening the health of the population, especially children, and reducing the complications of the disease through the development of modern, new methods of diagnosing and treating hereditary diseases are of great importance.

Purpose: The aim of this study is to identify regional clinical and laboratory characteristics of the disease in order to improve the effectiveness of diagnosis and complex treatment of bronchopulmonary pathology in children with cystic fibrosis in the Aral Sea region.

Results and their discussion: The dynamics of the main clinical symptoms in the complex treatment of cystic fibrosis patients in the Aral Sea region was expressed in the fact that in groups II and III, intoxication symptoms were eliminated in a very short time, the cough became much softer and moist, and physical data also had a very clear positive dynamics compared to group I ($p<0.05$ and $p<0.01$). On percussion, in patients of groups II–III, against the background of complex therapy, the box type of percussion sound was detected only for fewer days than in the group receiving basic therapy ($p<0.01$ and $p<0.001$). On auscultation, moist and dry rales were heard against the background of heavy breathing in patients of groups II–III for fewer days than in children in the group receiving basic therapy ($p<0.05$ and $p<0.01$). The length of hospital stay of patients who received complex treatment measures decreased to 9.6±0.2 days/day in group III, while in group I these figures were 11.5±0.3 days ($p<0.01$).

When studying TNF after complex therapy in patients of groups II and III, it was shown that the levels of NF1, TSH, Tiffno index and NF100 significantly increased compared to the initial data, as well as the results obtained in patients of group I after treatment. When assessing the results of the dynamic assessment of TNF indicators, no reliable recovery of the normative indicators was observed in group I ($p>0.05$). In children of groups II and III, a significant improvement in TNF indicators was observed compared to children of group I who received basic therapy. NF1 in groups II and III increased by 1.4 and 1.6 times compared to the initial data, being 71.8±1.5 and 82.03±1.8, respectively. Compared with children of group I, it was significantly higher by 1.3 and 1.5 times ($p<0.05$; $P<0.01$). The level of TSH was 1.2 times higher than in group I, amounting to 70.4±1.4

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

(p<0.05), and compared with the initial data, it was 1.3 times higher. In group III, the level of TSH was 1.4 times higher (84.5±3.0; p<0.05) and practically approached the indicators of healthy children. Re-examination of C-reactive protein and procalcitonin, which are biomarkers of inflammation, in the context of differentiated therapy was of particular scientific and practical interest. When analyzing the complex treatment of C-reactive protein and procalcitonin indicators in children with MV, positive effectiveness was revealed (Fig. 7).




Figure 7. Dynamics of S-reactive protein indicators in children with MV, M±m.

From the presented data, it can be seen that after complex treatment in children with MV in groups II and III, a significant decrease in SRO indicators was noted to 22.3±2.0 mg/l and to 8.2±1.8 mg/l, respectively, compared with group I (p<0.05 and p<0.01).

This indicator in children in group III showed a more significant decrease by 3.9 times compared with children in group I and 2.7 times compared with group II indicators. The results of data analysis showed a significant decrease in PCT indicators in children in groups II and III to 2.6±0.6 ng/l and 0.4±0.06 ng/l and to 5.1±0.8 ng/l, respectively, compared with group I indicators (p<0.05 and p<0.01).

The analysis of the results of PCT indicators revealed the following specific features: in children of group III, the PCT level was significantly reduced by 12.7 times compared to the values of group I and by 6.5 times compared to the values of children of group II.

Conclusion: In children with cystic fibrosis in the Aral Sea region, a 4.0-fold increase in C-reactive protein and a 5.9-fold increase in procalcitonin were found in bronchopulmonary pathology compared to the control group (p<0.001), which is an informative indicator in the differential diagnosis of bacterial infection and is a criterion for timely monitoring of the effectiveness of antibacterial therapy in children with this pathology.

References.

1. Шамсиев, Ф. М., Узакова, Ш. Б., & Атажанов, Х. П. (2022). кЛинико-ЛаБораторные оСоБенноСти муковиСцидоЗа у детеЙ. *FORCIPE*, *5*(S2), 542-543.
2. Атажанов, Х. П. (2025). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ БРОНХОЛЕГОЧНОЙ ПАТОЛОГИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ. *Multidisciplinary Journal of Science and Technology*, *5*(2), 438-443.
3. Атажанов, Х. П. (2025). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ БРОНХОЛЕГОЧНОЙ ПАТОЛОГИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ. *Multidisciplinary Journal of Science and Technology*, *5*(2), 438-443.
4. Атажанов, Х. П. (2025). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ БРОНХОЛЕГОЧНОЙ ПАТОЛОГИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ. *Multidisciplinary Journal of Science and Technology*, *5*(2), 438-443.
5. Атажанов, Х. П. (2025). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ БРОНХОЛЕГОЧНОЙ ПАТОЛОГИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ. *Multidisciplinary Journal of Science and Technology*, *5*(2), 438-443.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

6. Атажанов, Х. П. (2025). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ БРОНХОЛЕГОЧНОЙ ПАТОЛОГИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ. *Multidisciplinary Journal of Science and Technology*, *5*(2), 438-443.
7. Атажанов, Х. П., & Оллаберганова, Ш. М. (2025). ОСОБЕННОСТИ ТЕЧЕНИЯ ГОСПИТАЛЬНОЙ ПНЕВМОНИИ У ДЕТЕЙ. *Journal of Multidisciplinary Innovation in Science and Education*, *1*(3), 105-109.
8. Атажанов, Х. П., & Оллаберганова, Ш. М. (2025). ОСОБЕННОСТИ ТЕЧЕНИЯ НОЗОКОМИАЛЬНОГО СЕПСИСА У ДЕТЕЙ. *Journal of Multidisciplinary Innovation in Science and Education*, *1*(3), 123-126.
9. Nazarov, K. D., Ganiev, A. G., Efimenko, O., & Botirov, A. R. (2018). IMMUNOLOGICAL MECHANISMS OF DEVELOPMENT OF COMPLICATED FORMS OF ATOPIC DERMATITIS. *Central Asian Problems of Modern Science and Education*, *3*(3), 39-43.
10. Машарипова, Х. К. (2022). ОБЩИЙ ПЕЧЕНОЧНЫЙ ПРОТОК У ДЕТЕЙ В ПОСТАТАЛЬНОМ ОНТОГЕНЕЗЕ. In *НАУЧНОЕ ОБОЗРЕНИЕ: АКТУАЛЬНЫЕ ВОПРОСЫ ТЕОРИИ И ПРАКТИКИ* (pp. 242-244).
11. Машарипова, Х. К., & Салаева, З. Ш. (2020). Часто болеющие дети в Хорезмском регионе. *European science*, (1 (50)), 66-69.
12. Аскарова, Р. И., Машарипова, Ш. С., Атажанов, Ш. З., Машарипова, Х. К., & Якубова, У. Б. (2019). ОСОБЕННОСТИ ТЕЧЕНИЯ БЕРЕМЕННОСТИ ЖЕНЩИН, БОЛЬНЫХ ТУБЕРКУЛЁЗОМ ОРГАНОВ ДЫХАНИЯ. In *International scientific review of the problems of natural sciences and medicine* (pp. 202-209).
13. Машарипова, Х. К. (2022). ОБЩИЙ ПЕЧЕНОЧНЫЙ ПРОТОК У ДЕТЕЙ В ПОСТАТАЛЬНОМ ОНТОГЕНЕЗЕ. In *НАУЧНОЕ ОБОЗРЕНИЕ: АКТУАЛЬНЫЕ ВОПРОСЫ ТЕОРИИ И ПРАКТИКИ* (pp. 242-244).
14. Машарипова, Х. К., & Машарипов, А. С. (2019). ЭКСТРАЦЕРЕБРАЛЬНАЯ ПАТОЛОГИЯ ДЫХАТЕЛЬНОЙ СИСТЕМЫ ПРИ ЧЕРЕПНО-МОЗГОВОЙ ТРАВМЕ. *Новый день в медицине*, (4), 207-211.
15. Машарипова, Х., Усманов, Р., & Ахмедова, С. (2020). Анатомическое строение печени детей разного возраста. *Журнал вестник врача*, *1*(4), 36-42.